Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes.
about
An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.Comparison of the efficacy and safety of insulin glargine and insulin detemir with NPH insulin in children and adolescents with type 1 diabetes mellitus receiving intensive insulin therapy.A review of the pharmacological properties of insulin degludec and their clinical relevance.Insulin detemir in a twice daily insulin regimen versus a three times daily insulin regimen in the treatment of type 1 diabetes in children: A pilot randomized controlled trialInsulin Detemir Is Transported From Blood to Cerebrospinal Fluid and Has Prolonged Central Anorectic Action Relative to NPH Insulin.Insulin detemir in the treatment of type 1 and type 2 diabetes.Insulin detemir--a new basal insulin analog.Treatment of transient neonatal diabetes mellitus with subcutaneous insulin glargine in an extremely low birth weight neonate.3-Month Results from Denmark within the Globally Prospective and Observational Study to Evaluate Insulin Detemir Treatment in Type 1 and Type 2 Diabetes: The PREDICTIVE Study.Safety and side effects of the insulin analogues.Common crossroads in diabetes management.Paediatric diabetes: achieving practical, effective insulin therapy in type 1 and type 2 diabetes.New developments in the treatment of type 1 diabetes in children.Insulin aspart in diabetic pregnancy: state of the art.How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes.Treatment options for paediatric diabetes.Analog insulin detemir for patients with type 1 and type 2 diabetes: a review.Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs.Insulin detemir: a review of its use in the management of diabetes mellitus.An update on the pharmacotherapy options for pediatric diabetes.Insulin detemir: a new option for the treatment of diabetes.Comparison of human insulin and insulin analogues on hypoglycaemia and metabolic variability in type 1 diabetes using standardized measurements (HYPO score and Lability Index).Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes.Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus.Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus.The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial
P2860
Q33902616-9C95B756-86AC-428A-AAE0-526685407F3DQ34423102-2D480696-8E83-46D4-B0E2-4B4BAAAA4802Q34436383-335671B4-88B1-44DF-A69C-87F6C8970F61Q35570360-C0F51808-6139-48F0-BCB9-D86E6A27DFC0Q35769593-2DB7828A-68DA-49D6-B79C-C2FF5FC6F656Q36012958-43B69C38-5FA6-4079-B27D-3E689F1EDFD6Q36013053-520442DE-7F25-4140-B54D-3B9E430D18A3Q36063814-9EB4ECD0-C994-45A0-8460-0CB6EAAE8EDAQ36084624-1B77FCDF-2930-4DCD-844B-23BACA592EC5Q36349754-94C3DBC5-7E4E-4935-90D4-D77A31EC99F7Q36511814-EAAFE9A1-F806-4661-823B-7C90DFA74EFFQ36971945-6D2B65D6-AC5E-4148-AE12-71F33D062DE1Q36978565-039BB8CC-8561-484E-82F8-844C9F0B65B3Q37346167-8F8A2673-4B70-4A75-B0A9-9BF44C4BCDB6Q37771436-59096688-46C2-41EC-BF53-9F62B331E263Q37776269-D3DB622D-FF49-4DF6-9DD8-1982407CDE2AQ37857693-AEB5DF1E-1FA5-4377-9AEB-36B3B06DB053Q37893971-FF8A72BA-FB75-40B1-A177-A8EED3002818Q38056540-5EC5ACBF-71CE-46C9-9366-BCFBA6917184Q38175521-6A18E3EE-AAE8-4C50-84BF-C17A30AB72A3Q42519403-95B76AEF-1848-4564-82E6-45F4C7078CE2Q44554152-9F64E427-11E1-42F4-AD29-7F3E8EE595A2Q51280317-A1D17A54-82EE-4B0D-924E-90DFC362ECD7Q51332885-40D1611C-0138-4EF8-93B6-017E90925AE5Q51376686-DB41EB97-1C13-4E6B-9D55-96D7E498DCFAQ53449720-B92AA878-ED85-4777-B5FE-D44BB5E5FF5EQ58775144-83650A2D-8814-4293-B443-0020366F9E7E
P2860
Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Insulin detemir is characteriz ...... d adults with type 1 diabetes.
@en
Insulin detemir is characteriz ...... d adults with type 1 diabetes.
@nl
type
label
Insulin detemir is characteriz ...... d adults with type 1 diabetes.
@en
Insulin detemir is characteriz ...... d adults with type 1 diabetes.
@nl
prefLabel
Insulin detemir is characteriz ...... d adults with type 1 diabetes.
@en
Insulin detemir is characteriz ...... d adults with type 1 diabetes.
@nl
P2093
P921
P1433
P1476
Insulin detemir is characteriz ...... d adults with type 1 diabetes.
@en
P2093
Kerstin Lüpke
Kerstin Walte
Mari-Anne Gall
Thomas Danne
Wolfgang Von Schuetz
P304
P356
10.2337/DIACARE.26.11.3087
P407
P577
2003-11-01T00:00:00Z